NCT06476834

A Study Evaluating Deucravacitinib Concentrations in the Breast Milk and Plasma of Healthy Lactating Female Participants

A Phase IV, Open-label, Single-group, Single-dose Study Evaluating Deucravacitinib Concentrations in the Breast Milk and Plasma of Healthy Lactating Female Participants

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 8 (actual)
• Sponsor: Bristol-Myers Squibb · Industry
• Sex: Female
• Age: 18 Years – 45 Years
• Healthy volunteers: Accepted

Summary

The purpose of this study is to evaluate Deucravacitinib concentrations in the breast milk and plasma of healthy lactating female participants.

Conditions

• Healthy Volunteers

Interventions

Type	Name	Description
DRUG	Deucravacitinib	Specified dose on specified days

Timeline

• Start date: 2024-06-24
• Primary completion: 2024-11-02
• Completion: 2024-11-02
• First posted: 2024-06-26
• Last updated: 2025-12-03
• Results posted: 2025-12-03

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study